|

Teclistamab Clinical Trials

21 actively recruiting trials across 11 locations

Also known as: (TECVAYLI™), JNJ 64007957, JNJ-64007957, JNJ64007957, No more information, TECVAYLI, Teclistamab-cqyv, Tecvayli, teclistamab-cqyv

Other9 trials

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
Phase 2
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3
A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma
Phase 4
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Phase 2
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma
Phase 2
Plan Development for Giving Teclistamab in the Outpatient Setting
Phase 4
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Phase 2
Study on the Clinical Efficacy of Teclistamab
The Norwegian Immunotherapy in Multiple Myeloma Study

Phoenix, Arizona2 trials

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Banner University Medical Center Tucson, University of Arizona

Phase 3
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma

Mayo Clinic Hospital in Arizona

Phase 1

Gilbert, Arizona1 trial

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3

Tucson, Arizona1 trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Arizona Oncology Associates

Phase 2

Clovis, California1 trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

UCSF Fresno

Phase 3

Duarte, California1 trial

MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM

City of Hope

Phase 2

Denver, Colorado1 trial

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Colorado Blood Cancer Institute

Phase 2

New Haven, Connecticut1 trial

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Yale University

Phase 2

Miami, Florida1 trial

Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

University of Miami

Phase 2

Atlanta, Georgia1 trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

Basking Ridge, New Jersey1 trial

A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

New York, New York1 trial

Teclistamab-Daratumumab in AL Amyloidosis

Columbia University Irving Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.